Breaking News Instant updates and real-time market news.

KALA

Kala Pharmaceuticals

$8.58

0.52 (6.45%)

16:47
10/12/18
10/12
16:47
10/12/18
16:47

Longitude Capital lowers stake in Kala Pharmaceuticals to 9.0% from 9.3%

The Reporting Persons hold the securities of the Issuer for general investment purposes.

KALA Kala Pharmaceuticals
$8.58

0.52 (6.45%)

08/23/18
WELS
08/23/18
NO CHANGE
WELS
Outperform
FDA approval of Kala's Inveltys 'very positive news,' says Wells Fargo
Wells Fargo analyst David Maris says FDA approval of Kala Pharmaceuticals' Inveltys for post-operative pain inflammation and pain following ocular surgery is "very positive news." The analyst notes that Inveltys is the first and only twice- daily ocular steroid for this indication, as other products that are typically dosed at four times per day. Maris continue to believe Inveltys will be "very successful." He anticipates sales of approximately $25M in 2019, and $345M by 2025. The analyst keeps an Outperform rating on Kala amid the "sell-on-the-news reaction today."
08/24/18
HCWC
08/24/18
NO CHANGE
Target $37
HCWC
Buy
Kala Pharmaceuticals price target raised to $37 from $35 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Kala Pharmaceuticals to $37 after the FDA approved Inveltys for the treatment of post-operative inflammation and pain following all ocular surgeries. The approval is not only a risk-mitigating milestone for the company, but also crucial validation of its MPP technology, Selvaraju tells investors in a research note. The analyst reiterates a Buy rating on Kala Pharmaceuticals.
10/04/18
HCWC
10/04/18
NO CHANGE
Target $32
HCWC
Buy
Kala Pharmaceuticals price target lowered to $32 from $37 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju lowered his price target for Kala Pharmaceuticals to $32 after the company announced a public offering of 7.5M shares at $8.25 per share for gross proceeds of approximately $62M. The public offering and $75M term loan provide Kala sufficient capital for clinical development and commercialization, Selvaraju tells investors in a research note. The analyst reiterates a Buy rating on the shares.
10/04/18
WELS
10/04/18
NO CHANGE
Target $15
WELS
Outperform
Kala Pharmaceuticals price target lowered to $15 from $19 at Wells Fargo
Wells Fargo analyst David Maris lowered his price target for Kala Pharmaceuticals to $15 from $19 after the company announced the pricing of a secondary equity offering of 7.5M shares at $8.25, raising net proceeds of about $62M. Further, the company also announced a $110M credit facility with Athyrium Capital Management, with the first $75M tranche drawn immediately at an interest rate of 9.875%, the analyst notes. Maris points out that the stock sold off about 16%, reflecting the about 30% equity dilution and high interest cost of the debt, and says he believes the financing was executed "poorly" and at expensive terms. He reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

HSY

Hershey

$110.01

0.315 (0.29%)

12:09
02/20/19
02/20
12:09
02/20/19
12:09
Hot Stocks
Hershey reaffirms 2019 guidance at CAGNY Conference »

Hershey said that in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 03

    Mar

KNX

Knight-Swift

$34.96

0.73 (2.13%)

12:05
02/20/19
02/20
12:05
02/20/19
12:05
Options
Knight Transportation call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

12:05
02/20/19
02/20
12:05
02/20/19
12:05
General news
U.S. corporate bond update: the calendar remains active. »

U.S. corporate bond…

DNLI

Denali Therapeutics

$21.44

-0.16 (-0.74%)

12:03
02/20/19
02/20
12:03
02/20/19
12:03
Hot Stocks
Denali granted orphan status for mucopolysaccharidosis treatment »

The FDA granted Denali…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDY

Dr. Reddy's

$35.97

-0.45 (-1.24%)

12:03
02/20/19
02/20
12:03
02/20/19
12:03
Hot Stocks
Dr. Reddy's announces re-launch of buprenorphine, naloxone sublingual film »

Dr. Reddy's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

HSY

Hershey

$109.86

0.165 (0.15%)

12:01
02/20/19
02/20
12:01
02/20/19
12:01
Earnings
Hershey backs FY19 adjusted EPS growth view of 5%-7%, consensus $5.64 »

Backs FY19 net sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 03

    Mar

QTT

Qutoutiao

$12.66

0.25 (2.01%)

12:01
02/20/19
02/20
12:01
02/20/19
12:01
Downgrade
Qutoutiao rating change  »

Qutoutiao downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

BHC

Bausch Health

$23.23

-1.94 (-7.71%)

12:00
02/20/19
02/20
12:00
02/20/19
12:00
Hot Stocks
Bausch Health falls -7.7% »

Bausch Health is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 12

    Mar

  • 12

    Mar

IDT

IDT Corp

$6.48

-0.68 (-9.50%)

12:00
02/20/19
02/20
12:00
02/20/19
12:00
Hot Stocks
IDT Corp falls -9.1% »

IDT Corp is down -9.1%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMI

Owens & Minor

$6.62

-1.32 (-16.62%)

12:00
02/20/19
02/20
12:00
02/20/19
12:00
Hot Stocks
Owens & Minor falls -16.6% »

Owens & Minor is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

I

Intelsat

$24.38

2.755 (12.74%)

12:00
02/20/19
02/20
12:00
02/20/19
12:00
Hot Stocks
Intelsat rises 12.8% »

Intelsat is up 12.8%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 11

    Mar

  • 11

    Mar

QUAD

Quad/Graphics

$16.58

2.04 (14.03%)

12:00
02/20/19
02/20
12:00
02/20/19
12:00
Hot Stocks
Quad/Graphics rises 14.4% »

Quad/Graphics is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

LKSD

LSC Communications

$9.47

1.18 (14.23%)

12:00
02/20/19
02/20
12:00
02/20/19
12:00
Hot Stocks
LSC Communications rises 14.6% »

LSC Communications is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLNE

Clean Energy

$2.23

0.24 (12.06%)

11:58
02/20/19
02/20
11:58
02/20/19
11:58
Hot Stocks
Clean Energy jumps 12% after seeing demand increases for RNG from refuse sector »

Clean Energy Fuels,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Mar

  • 12

    Mar

TKC

Turkcell

$6.97

0.06 (0.87%)

11:56
02/20/19
02/20
11:56
02/20/19
11:56
Hot Stocks
Breaking Hot Stocks news story on Turkcell 

Turkcell trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 14

    Mar

  • 19

    Mar

DDAIF

Daimler AG

$0.00

(0.00%)

11:48
02/20/19
02/20
11:48
02/20/19
11:48
Periodicals
German prosecutors launch new probe into Daimler, Reuters reports »

Prosecutors in Germany…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

IQ

iQIYI

$22.76

0.43 (1.93%)

11:45
02/20/19
02/20
11:45
02/20/19
11:45
Options
iQiyi call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 20

    Mar

11:45
02/20/19
02/20
11:45
02/20/19
11:45
General news
Treasury's $18 B 2-year FRN reopening was a little soft »

Treasury's $18 B…

11:41
02/20/19
02/20
11:41
02/20/19
11:41
Conference/Events
UBS services analyst to hold an analyst/industry conference call »

Services Analyst Geiger,…

DVN

Devon Energy

$31.18

2.87 (10.14%)

11:41
02/20/19
02/20
11:41
02/20/19
11:41
Hot Stocks
Devon Energy sees FY19 total production 294-309 MBoe/d »

Sees FY19 oil production…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 27

    Feb

  • 28

    Feb

  • 22

    May

WIX

Wix.com

$110.04

-15.66 (-12.46%)

11:38
02/20/19
02/20
11:38
02/20/19
11:38
Recommendations
Wix.com analyst commentary  »

Wix.com strategy change…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 25

    Feb

  • 25

    Feb

  • 12

    Mar

  • 18

    Mar

11:35
02/20/19
02/20
11:35
02/20/19
11:35
General news
2-Yr FRN Note Auction Bid/Cover data reported »

2-Yr FRN Note Auction…

11:35
02/20/19
02/20
11:35
02/20/19
11:35
General news
2-Yr FRN Note Auction Total Amount data reported »

2-Yr FRN Note Auction…

DATA

Tableau

$128.02

1.08 (0.85%)

11:30
02/20/19
02/20
11:30
02/20/19
11:30
Options
Size time spread in Tableau Software paints a bullish picture »

Size time spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 06

    Mar

  • 07

    Mar

MO

Altria Group

$50.35

1.41 (2.88%)

11:26
02/20/19
02/20
11:26
02/20/19
11:26
Hot Stocks
Altria Group backs long-term adjusted EPS growth at 7%-9% annual rate »

In comments being…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.